The problem with IPCI's oxycontin NDA candidate it's at least a year away minimum from advancing through another adcom...and that's only if Dr. Odidi doesn't screw up the resubmission or the next adcom.
And this stock isn't gonna survive another full calendar year of the same ole same old dilutive financing Dr. Odidi's been securing in the post reverse split era.
There's simply been too much water that's passed under the bridge over the past 9 and a half years already to justify any market support in the post reverse split era.
Dr. Odidi was too arrogant and blind to stop the bleeding 4 and a half years ago when the FocalinXR debacle came along...and the moment he flips the switch on the reverse split next month it's all but over for any remaining IPCI retail longs for at least the next couple of years...and I honestly can't see IPCI even maintaining compliance with their NAZ listing in the post reverse split era because IMO there's gonna be endless downside pressure on the stock from all the dilution that gets immediately put into motion.
I hate having to be so negative...but it's better to view things objectively after how we've seen everything play out over the past 4 and a half years of never ending poor mgmt. decisions than hope for miracles that just aren't coming.
News 
Market Data 
Discover 
AI
